Format

Send to

Choose Destination
Blood Cancer J. 2018 Jun 11;8(6):55. doi: 10.1038/s41408-018-0081-8.

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

Author information

1
Yale University and Yale Cancer Center, New Haven, CT, USA. amer.zeidan@yale.edu.
2
Yale Cancer Outcomes Public Policy, and Effectiveness Research (COPPER) Center, New Haven, CT, USA. amer.zeidan@yale.edu.
3
Yale University and Yale Cancer Center, New Haven, CT, USA.
4
Yale Cancer Outcomes Public Policy, and Effectiveness Research (COPPER) Center, New Haven, CT, USA.
5
Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.
6
Department of Chronic Diseases, Yale School of Public Health, Yale University, New Haven, CT, USA.
7
Department of Health Policy and Management, School of Public Health, Yale University, New Haven, CT, USA.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center